Oral transmucosal fentanyl citrate for the treatment of breakthrough pain

被引：0
|
作者：
Zarth, R.
Ehmer, M.
Sittig, H. -B.
机构：
[1] Univ Tubingen, Akad Lehrkrankenhaus, Zollernalb Klinikum, Anaesthesiol & Intens Med Abt, D-72336 Balingen, Germany
[2] Praxis Schemerztherapie & Palliativ Med, Freiburg, Germany
[3] Spezielle Schmerztherapie Palliativ Med, MVZ Buntenskamp, Geesthacht, Germany
来源：
SCHMERZ | 2007年 / 21卷 / 06期
关键词：
cancer-related pain; breakthrough pain; oral transmucosal fentanyl citrate; observational study;
D O I：
10.1007/s00482-007-0590-z
中图分类号：
R614 [麻醉学];
学科分类号：
100217 ;
摘要：
In a non-interventional study the efficacy and tolerability of oral transmucosal fentanyl citrate (OTFC) was studied in patients with opioid-treated cancer pain suffering from breakthrough pain. The prospective multicenter observational trial included 406 patients. For 3-4 months, efficacy of OTFC treatment for breakthrough pain was documented using a numerical analog pain intensity scale (NAS). Further, OTFC therapy was rated and adverse events were recorded. With application of oral transmucosal fentanyl citrate median pain intensity fell from NAS 8 points at the beginning to NAS 2 points at the end of the study. The median effective dosage was 400 g. Tolerability was rated as good or very good by 87.5% of the patients. Oral transmucosal fentanyl citrate is a safe and effective treatment for breakthrough pain in chronic cancer-related pain.
引用
收藏
页码：545 / 552
页数：8
相关论文
共 50 条
  • [21] Oral transmucosal fentanyl citrate and xerostomia
    Davies, AN
    Vriens, J
    JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2005, 30 (06) : 496 - 497
  • [22] Oral transmucosal fentanyl citrate: Randomized, double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients
    Farrar, JT
    Cleary, J
    Rauck, R
    Busch, M
    Nordbrock, E
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (08): : 611 - 616
  • [23] Impact of breakthrough pain on quality of life in patients with chronic, noncancer pain:: Patient perceptions and effect of treatment with oral transmucosal fentanyl citrate (OTFC®, ACTIQ®)
    Taylor, Donald R.
    Webster, Lynn R.
    Chun, Steven Y.
    Reinking, Jeffrey
    Stegman, Mary
    Shoemaker, Steven
    Fortner, Barry
    PAIN MEDICINE, 2007, 8 (03) : 281 - 288
  • [24] A new transmucosal fentanyl for breakthrough cancer pain
    Rospond, RM
    CANCER PRACTICE, 1999, 7 (06) : 317 - 320
  • [25] ORAL TRANSMUCOSAL FENTANYL CITRATE AS A PREMEDICATION IN ADULTS
    CONNELLY, AM
    MACALUSO, AD
    HAYES, WB
    HOLUB, MC
    RAMSAY, MAE
    COON, R
    SUIT, CT
    HEIN, HAT
    ANESTHESIOLOGY, 1995, 83 (3A) : A302 - A302
  • [26] ORAL TRANSMUCOSAL FENTANYL CITRATE PREMEDICATION IN CHILDREN
    STREISAND, JB
    STANLEY, TH
    HAGUE, B
    VANVREESWIJK, H
    HO, GH
    PACE, NL
    ANESTHESIA AND ANALGESIA, 1989, 69 (01): : 28 - 34
  • [27] Oral transmucosal fentanyl citrate for premedication in adults
    Macaluso, AD
    Connelly, AM
    Hayes, WB
    Holub, MC
    Ramsay, MAE
    Suit, CT
    Hein, HAT
    Swygert, TH
    ANESTHESIA AND ANALGESIA, 1996, 82 (01): : 158 - 161
  • [28] ABSORPTION AND BIOAVAILABILITY OF ORAL TRANSMUCOSAL FENTANYL CITRATE
    STREISAND, JB
    VARVEL, JR
    STANSKI, DR
    LEMAIRE, L
    ASHBURN, MA
    HAGUE, BI
    TARVER, SD
    STANLEY, TH
    ANESTHESIOLOGY, 1991, 75 (02) : 223 - 229
  • [29] Oral transmucosal fentanyl citrate in cancer pain management: a practical application of nanotechnology
    Mystakidou, Kyriaki
    Tsilika, Eleni
    Tsiatas, Marinos
    Vlahos, Lambros
    INTERNATIONAL JOURNAL OF NANOMEDICINE, 2007, 2 (01): : 49 - 54
  • [30] Safety and efficacy of oral transmucosal fentanyl citrate for prehospital pain control on the battlefield
    Wedmore, Ian S.
    Kotwal, Russ S.
    McManus, John G.
    Pennardt, Andre
    Talbot, Timothy S.
    Fowler, Marcie
    McGhee, Laura
    JOURNAL OF TRAUMA AND ACUTE CARE SURGERY, 2012, 73 : S490 - S495
12345